HLA-E Antibody (4D12): sc-517455
- HLA-E Antibody (4D12) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised in HLA-B27 transgenic mice against the HLA-E protein of human origin
- recommended for detection of HLA-E of human origin by WB, IP, IF and FCM
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for HLA-E Antibody (4D12) for WB applications. These reagents are now offered in bundles with HLA-E Antibody (4D12) (see ordering information below).
QUICK LINKS
SEE ALSO...
HLA-E Antibody (4D12) is a mouse monoclonal IgG1 antibody that detects HLA-E in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). HLA-E is a crucial component of the immune system, functioning primarily as a non-classical major histocompatibility complex (MHC) class I molecule that presents a limited set of peptides to natural killer (NK) cells and CD8+ T lymphocytes. This selective peptide presentation is vital for immune regulation, as HLA-E plays a significant role in maintaining tolerance and preventing autoimmunity by interacting with inhibitory receptors on NK cells, such as NKG2A. The structure of HLA-E, which consists of a heavy chain non-covalently associated with β-2-Microglobulin, allows HLA-E to bind specific leader peptides derived from other MHC class I molecules, thereby modulating immune responses. The ability of HLA-E to present these peptides is essential for the recognition of infected or transformed cells, making HLA-E a key player in the immune surveillance process. Anti-HLA-E antibody (4D12) is therefore an invaluable tool for researchers studying immune responses, cellular interactions, and the intricate balance of activation and inhibition in the immune system.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HLA-E Antibody (4D12) References:
- HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells. | Pietra, G., et al. 2009. Curr Pharm Des. 15: 3336-44. PMID: 19860683
- Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. | Wieten, L., et al. 2014. Tissue Antigens. 84: 523-35. PMID: 25413103
- Human Antigen Leucocyte (HLA)-G and HLA-E are differentially expressed in pancreatic disorders. | Bertol, BC., et al. 2019. Hum Immunol. 80: 948-954. PMID: 31561913
- The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. | Borst, L., et al. 2020. Clin Cancer Res. 26: 5549-5556. PMID: 32409305
- HLA-E restricted cytomegalovirus UL40 peptide polymorphism may represent a risk factor following congenital infection. | Tarragó, D., et al. 2022. BMC Genomics. 23: 455. PMID: 35725386
- Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections. | Romero-Martín, L., et al. 2022. Front Immunol. 13: 1027855. PMID: 36466823
- The Impact of HLA-G and HLA-E Polymorphisms on CMV Reinfection in Liver Transplant Recipients. | Darai, M., et al. 2022. Iran J Immunol. 19: 404-413. PMID: 36585882
- XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. | Fisher, JG., et al. 2023. Leukemia. 37: 2036-2049. PMID: 37528310
- CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma. | Ismael, A., et al. 2024. Leukemia. 38: 1777-1786. PMID: 38902472
- Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies. | Weitzen, M., et al. 2024. Front Immunol. 15: 1442783. PMID: 39301027
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HLA-E Antibody (4D12) | sc-517455 | 200 µg/ml | $322.00 | |||
HLA-E Antibody (4D12): m-IgG Fc BP-HRP Bundle | sc-541109 | 200 µg Ab; 10 µg BP | $361.00 | |||
HLA-E Antibody (4D12): m-IgG1 BP-HRP Bundle | sc-542585 | 200 µg Ab; 20 µg BP | $361.00 |